NASDAQ:PYPD

Polypid Stock News

Healthcare > Biotechnology

Buy PYPD

*Your capital is at risk

$4.29

-0.0800 (-1.83%)

At Close: Jul 31, 2026

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

08:54am, Monday, 09'th Jun 2025

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

07:30am, Monday, 09'th Jun 2025

PETACH TIKVA, Israel, June 09, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

04:05pm, Friday, 06'th Jun 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today a

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

10:12am, Friday, 30'th May 2025

New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research b

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

07:00am, Tuesday, 20'th May 2025

PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will partic

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

01:24pm, Wednesday, 14'th May 2025

PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin -

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

07:00am, Wednesday, 14'th May 2025

PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100 , with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

07:00am, Tuesday, 29'th Apr 2025

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today a

PolyPid to Participate in The Citizens Life Sciences Conference

07:00am, Tuesday, 22'nd Apr 2025

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

07:00am, Tuesday, 11'th Mar 2025

PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today ann

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by